



Perspectives in Melanoma X and The Third International Melanoma Research Congress

**14-16 September 2006
The Netherlands**

*This program is presented under the auspices of the
European Organization for the Research and Treatment of Cancer*

For internal distribution only

This information is confidential and may not be shared with parties outside of the Imedex staff without prior approval.

Chairs of Perspectives X/ The Third International Melanoma Research Congress

Alexander M.M. Eggermont, MD, PhD
Erasmus University Medical Center
Daniel Den Hoed Cancer Center
Rotterdam, The Netherlands

Anja K. Bosserhoff, PhD
University of Regensburg
Regensburg, Germany

John M. Kirkwood, MD
University of Pittsburgh Medical Center
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States

Other Members Program Steering Committee SMR:

Chairs:

Meenhard Herlyn, DVM
The Wistar Institute
Philadelphia, Pennsylvania, United States

Julia Newton Bishop, MD
St James's University Hospital
Leeds, United Kingdom

Jeffrey S. Weber, MD, PhD
University of Southern California
Norris Comprehensive Cancer Center
Los Angeles, California, United States

Michael Detmar, MD
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts, United States

David E. Fisher, MD, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts, United States

Ze'ev A. Ronai, PhD
The Burnham Institute
La Jolla, California, United States

Alain Spatz, MD
Institut Gustave Roussy
Villejuif, France

Boris C. Bastian, MD
University of California,
San Francisco School of Medicine
San Francisco, California, United States

Dirk Ruiter, MD, PhD
Radboud University Nijmegen
Nijmegen, The Netherlands

Draft Scientific Agenda

Wednesday, 13 September 2006

EORTC Melanoma Group Program (working party)

Thursday, 14 September 2006

08:25 **Introductory Address**
Alexander M.M. Eggermont, MD, PhD

Keynote Address I

08:30 MITF and transcriptional regulation in melanocytes and melanoma
David E. Fisher, MD, PhD, Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, United States

Plenary Session I

Melanoblasts, Melanocytes and Melanoma: What Can We Learn From Embryogenesis?

Chair: *David E. Fisher, MD, PhD, Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, United States*

09:15 Introduction

09:20 Oncogene-induced senescence: *in-vitro* tool or *in-vivo* reality?
Daniel S. Peeper, PhD, The Netherlands Cancer Institute, Amsterdam, The Netherlands

09:50 Differentiation pathways for human melanocyte and melanoma stem cells
Meenhard Herlyn, DVM, The Wistar Institute, Philadelphia, Pennsylvania, United States

10:20 Proffered paper

10:35 Coffee Break

Concurrent Session IA:

Management of Malignant Melanoma: What are the New Markers for Diagnosis and Prognosis?

Chair: *DuPont Guerry, MD, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States*

11:00 Introduction

11:10 Validating the gene expression signatures of melanoma
Mohammed Kashani-Sabet, MD, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA, United States

- 11:35 Title to be determined
Anja K. Bosserhoff, PhD, University of Regensburg, Regensburg, Germany
- 12:00 Proffered paper
- 12:15 Proffered paper
- 12:30 Discussion

Concurrent Session IB

Optimization and Monitoring of Immunotherapy for Melanoma

Chair: *Jeffrey S. Weber, MD, PhD, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States*

- 11:00 Introduction
- 11:10 Dendritic cell vaccination: Novel immunomonitoring tools
Carl Figdor, PhD, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
- 11:35 Vaccination induced myeloid suppressor cells: phenotypic and functional characterization
Georgio Parmiani, MD, University of Milan/Istituto Nazionale Tumori, Milan, Italy
- 12:00 Proffered paper
- 12:15 Proffered paper
- 12:30 Discussion
- 12:40 **LUNCH**

Keynote Address II

- 13:45 **Critical barriers in development of immunotherapy**
Jeffrey S. Weber, MD, PhD, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States

Plenary Session II

Critical Barriers in Melanoma Tumor Immunology and Immunotherapy

Chair: *John M. Kirkwood, MD, University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States*

- 14:30 Introduction
- 14:40 Polarized dendritic cells as melanoma vaccines
Pawel Kalinski, MD, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States

15:10 Dendritic cell vaccination and amplification strategies
Gerold Schuler, MD, University Hospital Erlangen, Erlangen, Germany

15:40 Coffee Break

Concurrent Session IIA **Signalling and Targeted Therapies**

Chair: **Ze'ev A. Ronai, PhD, The Burnham Institute, La Jolla, California, United States**

16:00 Introduction

16:10 Stress responses in melanoma progression and chemoresistance
Maria Soengas, PhD, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

16:35 Mouse models for analysis of BRAF-induced cancer initiation and progression
Martin McMahon, PhD, UCSF Comprehensive Cancer Center, San Francisco, CA, United States

17:00 Proffered paper

17:15 Proffered paper

17:30 Discussion

Concurrent Session IIB **Genetics of Familial Melanoma and Molecular Epidemiology of Melanoma**

Chair: **Julia Newton Bishop, MD, St James's University Hospital, Leeds, United Kingdom**

16:00 Introduction

16:10 p16 in 2006- from point mutations to patients
Hensin Tsao, MD, PhD, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

16:35 p16 and p14ARF: So alike, so different
Nelleke A. Gruis, PhD, Leiden University Medical Center, Leiden, The Netherlands

17:00 Proffered paper

17:15 Proffered paper

17:30 Discussion

Poster Session

17:30 Poster discussant
Poster Awards (3)

18:00 Poster Viewing

19:30 Adjourn

20:00 **RECEPTION**

Friday, 15 September 2006

Keynote address III

08:30 Distinct patterns of somatic alterations in melanoma: Implications for classification, therapy, and prevention
Boris C. Bastian, MD, University of California, San Francisco School of Medicine, San Francisco, California, United States

Plenary Session III

Tumor Microenvironment and Drug Response

Chair: *Mary J.C. Hendrix, PhD, Children's Memorial Research Center, Northwestern University's Feinberg School of Medicine, Chicago, IL, United States*

09:15 Introduction

09:20 Vascular tumor targeting
Dario Neri, PhD, Swiss Federal Institute of Technology, Zurich, Switzerland

09:50 Extracellular matrix and control of melanoma proliferation
Yves A. De Clerk, MD, University of Southern California, Children's Hospital Los Angeles, Los Angeles, CA, United States

10:20 Proffered paper

10:35 Coffee Break

Concurrent session IIIA

Epigenetics

Chair: *Peter Jones, PhD, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States*

11:00 Introduction

11:05 How the epigenome changes in cancer
Peter Jones, PhD, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States

11:30 Epigenetic modulation of human melanoma: immunotherapeutic implications
Michele Maio, MD, PhD, University Hospital of Siena, Italy

11:55 Proffered paper

12:05 Proffered paper

12:15 Discussion

Concurrent Session IIIB:

System Biology for Development of Criteria for Selection for Therapy and Patient Follow Up

Chair: **Boris C. Bastian, MD, University of California, San Francisco School of Medicine, San Francisco, California, United States**

11:00 Introduction

11:05 Transcriptome modifications during melanoma progression: Implications for enriched patient population trial design
Alain Spatz, MD, Gustave Roussy Institute, Villejuif, France

11:30 Identification and exploration of pathways in melanoma: Implications for therapy
Ashani Weeraratna, PhD, National Institutes of Health, Bethesda, Maryland, United States

11:55 Proffered paper

12:10 Proffered paper

12:25 Discussion

12:35 **LUNCH**

Keynote Address IV

13:45 **Early metastatic disease: Diagnosis, SN and biologic understanding drive new management of melanoma**
Alexander M.M. Eggermont, MD, PhD, Erasmus University Medical Center Daniel Den Hoed Cancer Center Rotterdam, The Netherlands

Plenary Session IV

Biology of Early Metastasis

Chair: **Alexander M.M. Eggermont, MD, PhD, Erasmus University Medical Center Daniel Den Hoed Cancer Center Rotterdam, The Netherlands**

14:15 Biology of melanoma metastases in regional lymph nodes
Alistair J. Cochran, MD
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California

14:40 Proffered paper

14:55 Early detection of metastatic melanoma and monitoring assays for treatment response
David S.B. Hoon, MSc, PhD, John Wayne Cancer Institute, Santa Monica, CA, United States

- 15:20 Proffered paper
- 15:35 Discussion
- 15:35 Coffee Break

**Concurrent Session IVA
Transcriptional Regulation in Melanoma**

Chair: *Colin Goding, PhD, Marie Curie Research Institute, Surrey, United Kingdom*

- 16:00 Introduction
- 16:10 Title to be determined
Marianne Broome-Powell, PhD, Stanford University, Stanford, California, United States
- 16:35 Functional genetic approaches to melanoma
René Bernards, PhD, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- 17:00 Proffered paper
- 17:15 Discussion

**Concurrent Session IVB
Advances in Murine Melanoma Models**

Chair: *James J. Mulé, PhD, Lee Moffit Cancer Center and Research Institute, Tampa, Florida, USA*

- 16:00 Introduction
- 16:10 Regulating regulatory cells: Novel preclinical strategies headed for the clinic
Bernard A. Fox, PhD, Providence Portland Medical Center, Portland, Oregon, United States
- 16:35 Suppressors of cytokine signaling: A pair of SOCS
William E. Carson, III, MD, Ohio State University, Columbus, Ohio, United States
- 17:00 Proffered paper
- 17:15 Discussion

Poster Session

- 17:40 Poster discussant
Poster Awards (3)
- 18:10 Poster Viewing

19:30 Adjourn
20:00 Social Activities

Saturday, 16 September 2006

Keynote Address V

08:30 Tumor angiogenesis, lymphangiogenesis and melanoma metastasis
Michael Detmar, MD, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States

Plenary Session V

Plasticity of Melanoma Cells: Dynamic Changes During Tumor Development and Progression

Chair: *Anja K. Bosserhoff, PhD, University of Regensburg, Regensburg, Germany*

09:15 Introduction

09:20 Plasticity of human melanoma cells: Role of the microenvironment
Mary J.C. Hendrix, PhD, Children's Memorial Research Center, Northwestern University's Feinberg School of Medicine, Chicago, IL, United States

09:50 Catenin/cadherin and melanoma progression
Lionel Larue, PhD, Institut Curie, Orsay, France

10:20 Proffered paper

10:35 Discussion

10:50 Coffee Break

Plenary Session VI

Apoptosis and Cell Cycle in Melanoma

Chair: *Maria Soengas, PhD, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States*

11:00 Introduction

11:10 To be determined
Neal Rosen, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, New York, United States

11:40 Mda-7/IL-24: Novel cancer-specific apoptosis-inducing cytokine
Paul B. Fisher, PhD, Columbia University Medical Center, New York, New York, United States

12:10 Proffered paper

12:25 Discussion

12:30 **Lunch Symposium:**
Recent Clinical Trials in Melanoma
Moderators: *Ulrich Keilholz, MD, Charité Campus Benjamin Franklin, Berlin, Germany* and *John M. Kirkwood, MD, University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States*

Special Symposium

Melanoma Workshop: Novel Concepts in Basic Research Reaching the Clinic

Chair: *Meenhard Herlyn, DVM, The Wistar Institute, Philadelphia, Pennsylvania, United States*

14:00 **Discussion: Targeted therapies/targeted immunotherapies**
Moderator: Meenhard Herlyn, DVM

Participants: *Clinicians:*
John M. Kirkwood, MD
Keith Flaherty, MD
Alexander M.M. Eggermont, MD, PhD
Ulrich Keilholz, MD
Jeffrey Weber, MD
Gerold Schuler, MD

Scientists:
Rhoda Alani, PhD
Neal Rosen, MD, PhD
David Fisher, MD, PhD
Ze'ev Ronai, PhD
Rene Bernards, MD
Alain Spatz, MD

16:00 ADJOURN